Drug Profile
INB 200
Alternative Names: Allogeneic gamma-delta T-cells immunotherapies - IN8bio; CliniMACS Alpha Beta T-Cell Depletion System - IN8bio; CliniMACS-Prodigy - IN8bio; DeltEx DRI - IN8bio; DeltEx Drug Resistant Immunotherapy - IN8bio; EAGD T-cell infusion; INB-200Latest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Incysus
- Developer IN8bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
- Preclinical Solid tumours